Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Andexxa
Pharma
J&J, AZ approval filings rejected by FDA
The FDA has sent CRLs to J&J and AstraZeneca, rejecting J&J's application for subcutaneous Rybrevant and AZ's bid for a full approval of Andexxa.
Kevin Dunleavy
Dec 17, 2024 10:02am
FDA raises safety flags ahead of adcomm for AZ's Andexxa
Nov 20, 2024 8:33am
AZ's bleeding reversal agent Andexxa meets trial endpoint early
Jun 5, 2023 1:53pm
Alexion gives updated look at what AZ's getting for $39B
Jan 12, 2021 11:20am
Alexion bets $1.4B on Portola's laggard bleeding drug Andexxa
May 5, 2020 11:08am
Production of Portola's Andexxa underway—News of Note
Feb 7, 2019 12:00am
